title: Novel dosage forms and regimens for sevelamer-based phosphate binders.
abstract: Sevelamer, a nonabsorbed, calcium- and metal-free dietary phosphate binder, consists of a polyallylamine polymer backbone with a cationic charge that shows a high capacity for binding anionically charged compounds such as phosphate. The currently licensed form of sevelamer, Renagel, exists as sevelamer hydrochloride, which disassociates in the acidic environment of the stomach and early gastrointestinal tract, exchanging the chloride ions attached to the polymer backbone for phosphate ions. The resulting absorption of these chloride ions has been reported to be accompanied by a reduction in serum levels of bicarbonate in some patients. To minimize the possibility of this effect, a new salt form of sevelamer has been developed in which carbonate replaces the chloride counter ion, thereby providing a source of buffer. The majority of phosphate binders exist only in tablet form and are dosed three times per day with meals. Genzyme has developed sevelamer carbonate in tablet form and also as a powder formulation that can be taken after mixing with water. This allows for an alternate and potentially more palatable way of dosing. Preliminary data exist suggesting that once daily dosing with sevelamer hydrochloride tablets provides similar phosphate control to three times daily dosing. By providing novel dosage forms and regimens for sevelamer-based phosphate binders, Genzyme will be providing patients and health care providers additional choices and flexibility in controlling phosphorus levels in chronic kidney disease. This should translate to increased compliance and improved rates of phosphate control.
authors.affiliation: Genzyme Europe Research, Cambridge, England. ajay.duggal@genzyme.com
authors.forename: Ajay
authors.initials: A
authors.lastname: Duggal
authors.forename: Martin
authors.initials: M
authors.lastname: Hanus
authors.forename: Eugene
authors.initials: E
authors.lastname: Zhorov
authors.forename: Rafif
authors.initials: R
authors.lastname: Dagher
authors.forename: Melissa A
authors.initials: MA
authors.lastname: Plone
authors.forename: Jeffrey
authors.initials: J
authors.lastname: Goldberg
authors.forename: Steven K
authors.initials: SK
authors.lastname: Burke
mesh_terms: D000818:Animals; D001639:Bicarbonates / Q000097:blood; D002712:Chlorides / Q000737:chemistry; D004285:Dogs; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications* / Q000628:therapy*; D007700:Kinetics; D010349:Patient Compliance; D010710:Phosphates / Q000097:blood* / Q000737:chemistry; D010758:Phosphorus / Q000097:blood; D011073:Polyamines / Q000008:administration & dosage* / Q000737:chemistry / Q000493:pharmacokinetics; D006435:Renal Dialysis; D000069603:Sevelamer
chemical_list: D001639:Bicarbonates; D002712:Chlorides; D010710:Phosphates; D011073:Polyamines; D010758:Phosphorus; D000069603:Sevelamer